Assessing the Effect of Patient Characteristics on Treatment Response in Primary Hyperhidrosis
NCT ID: NCT03694093
Last Updated: 2020-02-05
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Total Enrollment
41 participants
Study Classification
OBSERVATIONAL
Study Start Date
2018-08-20
Study Completion Date
2019-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study will describe the treatment of hyperhidrosis (excessive sweating) in clinical practice and explore the effect of patient characteristics on treatment response. This study will follow 200 people with hyperhidrosis over 18 months. Anyone with primary hyperhidrosis (excessive sweating not due to another medical condition) over the age of 12 may participate. Study participants will have multiple office visits during which they will asked to rate the severity of their sweat production in multiple areas (i.e. underarms, hands, feet), answer a questionnaire regarding their disease and treatment, and undergo a non-invasive measurement of sweat production called gravimetry. Gravimetry is performed by placing absorbent material in an area, such as the underarms, for a set amount of time and then measuring the amount of sweat collected. In between clinic visits, study participants will be contacted electronically to answer several questions regarding their disease and treatment.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Thoracoscopic Sympathetic Chain Interruption for Palmar Hyperhidrosis in Patients Below 18
NCT06113978
Hyperhidrosis
Children, Adolescents
Thoracoscopic Sympathetic Chain Interruption
+1 more
COMPLETED
NA
An Open Label Study for Palmar Hyperhydrosis
NCT04906655
Palmar Hyperhidrosis
Hyperhidrosis
Sweat Gland Diseases
+1 more
COMPLETED
PHASE2
Evaluation of Phenotypic and Genetic Properties in Male Subjects Affected by Hypohidrotic Ectodermal Dysplasia - A
NCT01293565
Hypohidrotic Ectodermal Dysplasia
COMPLETED
A Cross-Sectional Natural History Study to Evaluate Sweat Volume and Other Phenotypic and Genetic Characteristics in Patients Affected by XLHED
NCT03912792
XLHED
WITHDRAWN
Impact of Dysregulation of Core Body Temperature on Sleep in Patients With Hypohidrotic Ectodermal Dysplasia
NCT05378932
Hypohidrotic Ectodermal Dysplasia
COMPLETED
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Subject Recruitment
Recruitment will take place at SLUCare Dermatology Des Peres Clinic. Patients with non-study related appointments with Dr. Glaser regarding the management of primary hyperhidrosis will be approached by a research member. Patients will be given ample time to review study design and have questions and concerns addressed. After inclusion and exclusion criteria, study purpose and design, signed consent (parent or guardian will sign if subject is a minor), assent (for minors only, not signed) and HIPAA release are attained, the patients will be enrolled in the study.
The investigators will be recruiting two types of patients for this study. (1) New patients being seen for evaluation for primary hyperhidrosis. These subjects will be presenting to the hyperhidrosis clinic for the first time. If enrolled, these subjects will have all data prospectively collected. (2) Established patients being seen for ongoing management of primary hyperhidrosis who have documented baseline gravimetric measurements (defined as measurements taken while the patient was undergoing no active therapies for primary hyperhidrosis). These subjects will be presenting to the hyperhidrosis clinic for continued care. If enrolled, these subjects will have some data collected retrospectively with the remainder collected prospectively (see below for details).
Withdrawal or Discontinuation
Subjects may withdraw from the study at any time. If a subject desires withdraw from the study, the subject will be give a reason for study withdraw which will be included in publication. If a subject misses a scheduled visit the subject will be contacted via phone to ask if the subject is withdrawing from the study or reschedule a visit.
Because the subjects are only undergoing gravimetry, a non invasive way of measuring sweat production, it is highly unlikely that there would be any reason to discontinue a subjects participation due to safety. However, if at any point the supervising provider feels that a patient is at risk of harm the subject may be withdrawn from the study. In this case, a reason would be recorded for publication purposes.
Screen Failures
For those that fail screening, all information collected prior to that time will be shredded and disposed of in confidentiality trash bins. Only a reason for failing to pass screening will be recorded for publication purposes.
Subject Visits
Subjects will be screened, sign consent (parent or guardian will sign if subject is a minor), review assent (only applicable to minors) HIPAA release, and enrolled at an initial visit. Patients will have a monthly electronic or telephone survey to fill out. Patients will be seen every 3 months in clinic until the patient has achieved treatment response and/or no treatment changes are required. 6 months after this visit, the patient will be seen in clinic again\*\*\*. If the subject has a sustained treatment response and/or has no treatment change, the subject will exit the study. If these conditions are not met, then the subject will resume 3 month visits.
It is important to note that these visit will overlap with non-study related visits that occur as a part of management of the patient's disease. Disease management decisions, such as which therapy to prescribe, will occur independently of this study and will not be affected by study participation. All visits will occur within 18 months after the study begins. No further study encounters will occur after this time period regardless of treatment changes or response.
\*\*\* Subjects may choose to forgo this 6 months visit and complete it electronically or by telephone.
New Patient
Subject Visit 1, 1 hour:
The subject will first verify his or her name and contact information. After the subject agrees to study participation they will sign a consent (permission) and a release of health information. Consent will be signed by parent or guardian if the subject is a minor. If the subject is a minor assent will also be reviewed with the subject. Inclusion and exclusion criteria will be reviewed.
Through an interview with a research team member and chart review, the following data will be collected:
* Basic demographics
* Current treatments
* Hyperhidrosis Disease Severity Scale score (a scale that rates how the subject feels sweating affects daily activities) for all sites:
* Scalp
* Face
* Underarms
* Inframammary
* Chest
* Back
* Hands
* Feet
* Groin
* Buttocks
* Questionnaire regarding the subject's disease state (see attachment).
Patients will then undergo gravimetric measurements of all sites affected by hyperhidrosis as detailed in the attachment. Areas affected by HH will be defined by areas with an HDSS 3 or greater. For details on the gravimetry protocol, see attachment.
Subject Visits, follow-up, 30 minutes:
The following data will be collected through subject interview:
* Current treatment
* HDSS for all sites.
* Questionnaire regarding the subject's disease state (see attachment).
* Presence or absence of side effects
Patients will then undergo gravimetric measurements for sites with previous measurements. For detailed protocol see attachment.
Established Patient
Subject Visit 1, 1 hour:
The subject will first verify his or her name and contact information. After the subject agrees to study participation they will sign a consent (permission) and a release of health information. Consent will be signed by parent or guardian if the subject is a minor. If the subject is a minor assent will also be reviewed with the subject. Inclusion and exclusion criteria will be reviewed.
Through chart review, the following data will be collected:
* Baseline (defined as data collected while the patient was not undergoing any treatment) HDSS score and gravimetric measurements for all sites
* Number of treatment changes since initiating care
* Basic demographics
Through an interview with the patient, the following information will be collected:
* Current treatment
* HDSS score for all sites
* Questionnaire regarding the subject's disease state (see attachment).
* Presence or absence side effects
Patients will then undergo gravimetric measurements for sites with previous gravimetric measurements.
Subject Visit, follow-up 30 minutes:
This will be the same as new patient follow up visits.
Subject Electronic/Telephone Survey: Monthly, 15 minutes
The following data will be collected through a phone or electronic interview between a research team member and the subject:
\- Questionnaire regarding the subject's disease state (see attachment).
Recruitment will take place at SLUCare Dermatology Des Peres Clinic. Patients with non-study related appointments with Dr. Glaser regarding the management of primary hyperhidrosis will be approached by a research member. Patients will be given ample time to review study design and have questions and concerns addressed. After inclusion and exclusion criteria, study purpose and design, signed consent (parent or guardian will sign if subject is a minor), assent (for minors only, not signed) and HIPAA release are attained, the patients will be enrolled in the study.
The investigators will be recruiting two types of patients for this study. (1) New patients being seen for evaluation for primary hyperhidrosis. These subjects will be presenting to the hyperhidrosis clinic for the first time. If enrolled, these subjects will have all data prospectively collected. (2) Established patients being seen for ongoing management of primary hyperhidrosis who have documented baseline gravimetric measurements (defined as measurements taken while the patient was undergoing no active therapies for primary hyperhidrosis). These subjects will be presenting to the hyperhidrosis clinic for continued care. If enrolled, these subjects will have some data collected retrospectively with the remainder collected prospectively (see below for details).
Withdrawal or Discontinuation
Subjects may withdraw from the study at any time. If a subject desires withdraw from the study, the subject will be give a reason for study withdraw which will be included in publication. If a subject misses a scheduled visit the subject will be contacted via phone to ask if the subject is withdrawing from the study or reschedule a visit.
Because the subjects are only undergoing gravimetry, a non invasive way of measuring sweat production, it is highly unlikely that there would be any reason to discontinue a subjects participation due to safety. However, if at any point the supervising provider feels that a patient is at risk of harm the subject may be withdrawn from the study. In this case, a reason would be recorded for publication purposes.
Screen Failures
For those that fail screening, all information collected prior to that time will be shredded and disposed of in confidentiality trash bins. Only a reason for failing to pass screening will be recorded for publication purposes.
Subject Visits
Subjects will be screened, sign consent (parent or guardian will sign if subject is a minor), review assent (only applicable to minors) HIPAA release, and enrolled at an initial visit. Patients will have a monthly electronic or telephone survey to fill out. Patients will be seen every 3 months in clinic until the patient has achieved treatment response and/or no treatment changes are required. 6 months after this visit, the patient will be seen in clinic again\*\*\*. If the subject has a sustained treatment response and/or has no treatment change, the subject will exit the study. If these conditions are not met, then the subject will resume 3 month visits.
It is important to note that these visit will overlap with non-study related visits that occur as a part of management of the patient's disease. Disease management decisions, such as which therapy to prescribe, will occur independently of this study and will not be affected by study participation. All visits will occur within 18 months after the study begins. No further study encounters will occur after this time period regardless of treatment changes or response.
\*\*\* Subjects may choose to forgo this 6 months visit and complete it electronically or by telephone.
New Patient
Subject Visit 1, 1 hour:
The subject will first verify his or her name and contact information. After the subject agrees to study participation they will sign a consent (permission) and a release of health information. Consent will be signed by parent or guardian if the subject is a minor. If the subject is a minor assent will also be reviewed with the subject. Inclusion and exclusion criteria will be reviewed.
Through an interview with a research team member and chart review, the following data will be collected:
* Basic demographics
* Current treatments
* Hyperhidrosis Disease Severity Scale score (a scale that rates how the subject feels sweating affects daily activities) for all sites:
* Scalp
* Face
* Underarms
* Inframammary
* Chest
* Back
* Hands
* Feet
* Groin
* Buttocks
* Questionnaire regarding the subject's disease state (see attachment).
Patients will then undergo gravimetric measurements of all sites affected by hyperhidrosis as detailed in the attachment. Areas affected by HH will be defined by areas with an HDSS 3 or greater. For details on the gravimetry protocol, see attachment.
Subject Visits, follow-up, 30 minutes:
The following data will be collected through subject interview:
* Current treatment
* HDSS for all sites.
* Questionnaire regarding the subject's disease state (see attachment).
* Presence or absence of side effects
Patients will then undergo gravimetric measurements for sites with previous measurements. For detailed protocol see attachment.
Established Patient
Subject Visit 1, 1 hour:
The subject will first verify his or her name and contact information. After the subject agrees to study participation they will sign a consent (permission) and a release of health information. Consent will be signed by parent or guardian if the subject is a minor. If the subject is a minor assent will also be reviewed with the subject. Inclusion and exclusion criteria will be reviewed.
Through chart review, the following data will be collected:
* Baseline (defined as data collected while the patient was not undergoing any treatment) HDSS score and gravimetric measurements for all sites
* Number of treatment changes since initiating care
* Basic demographics
Through an interview with the patient, the following information will be collected:
* Current treatment
* HDSS score for all sites
* Questionnaire regarding the subject's disease state (see attachment).
* Presence or absence side effects
Patients will then undergo gravimetric measurements for sites with previous gravimetric measurements.
Subject Visit, follow-up 30 minutes:
This will be the same as new patient follow up visits.
Subject Electronic/Telephone Survey: Monthly, 15 minutes
The following data will be collected through a phone or electronic interview between a research team member and the subject:
\- Questionnaire regarding the subject's disease state (see attachment).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Hyperhidrosis
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
CASE_ONLY
Study Time Perspective
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with Hyperhidrosis
Subjects with Primary Hyperhidrosis will be followed in this study. Because this study is observational, there will be no intervention.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Male or female of any race who has received the diagnosis of primary Hyperhidrosis at any site
2. Patients receiving continued treatment of primary Hyperhidrosis with baseline gravimetrics (established patients only) performed at SLUCare Dermatology Des Peres clinic. Baseline gravimetrics are defined as measurements taken during times of no active disease interventions.
2. Patients receiving continued treatment of primary Hyperhidrosis with baseline gravimetrics (established patients only) performed at SLUCare Dermatology Des Peres clinic. Baseline gravimetrics are defined as measurements taken during times of no active disease interventions.
Exclusion Criteria
1. Received the following therapies at the site being evaluated prior to baseline gravimetrics:
1. Botulinum toxin injections 6 months prior to baseline gravimetric data collection.
2. Applied Aluminum chloride on day of baseline gravimetric data
3. Ongoing iontophoresis therapy at time of baseline gravimetric data
4. Oral systemic anticholinergics 4 weeks prior to baseline gravimetric data
5. Received surgical intervention, suction and curettage, microwave thermolysis, or ultrasound therapy prior to baseline gravimetrics.
2. Patient has received diagnosis of secondary hyperhidrosis (i.e hyperhidrosis due to an underlying medical condition such as hyperthyroidism)
3. Younger than 12 years of age.
4. Does not desire study participation or is unable to consent.
1. Botulinum toxin injections 6 months prior to baseline gravimetric data collection.
2. Applied Aluminum chloride on day of baseline gravimetric data
3. Ongoing iontophoresis therapy at time of baseline gravimetric data
4. Oral systemic anticholinergics 4 weeks prior to baseline gravimetric data
5. Received surgical intervention, suction and curettage, microwave thermolysis, or ultrasound therapy prior to baseline gravimetrics.
2. Patient has received diagnosis of secondary hyperhidrosis (i.e hyperhidrosis due to an underlying medical condition such as hyperthyroidism)
3. Younger than 12 years of age.
4. Does not desire study participation or is unable to consent.
Minimum Eligible Age
12 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
St. Louis University
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dee Anna Glaser, MD
Interim Chair, Department of Dermatology
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dee A Glaser, MD
Role: PRINCIPAL_INVESTIGATOR
St. Louis University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Saint Louis University
St Louis, Missouri, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Hornberger J, Grimes K, Naumann M, Glaser DA, Lowe NJ, Naver H, Ahn S, Stolman LP; Multi-Specialty Working Group on the Recognition, Diagnosis, and Treatment of Primary Focal Hyperhidrosis. Recognition, diagnosis, and treatment of primary focal hyperhidrosis. J Am Acad Dermatol. 2004 Aug;51(2):274-86. doi: 10.1016/j.jaad.2003.12.029. No abstract available.
Reference Type
BACKGROUND
Glaser DA, Ballard AM, Hunt NL, Pieretti LJ, Pariser DM. Prevalence of Multifocal Primary Hyperhidrosis and Symptom Severity Over Time: Results of a Targeted Survey. Dermatol Surg. 2016 Dec;42(12):1347-1353. doi: 10.1097/DSS.0000000000000949.
Reference Type
BACKGROUND
Doolittle J, Walker P, Mills T, Thurston J. Hyperhidrosis: an update on prevalence and severity in the United States. Arch Dermatol Res. 2016 Dec;308(10):743-749. doi: 10.1007/s00403-016-1697-9. Epub 2016 Oct 15.
Reference Type
BACKGROUND
Basra MK, Fenech R, Gatt RM, Salek MS, Finlay AY. The Dermatology Life Quality Index 1994-2007: a comprehensive review of validation data and clinical results. Br J Dermatol. 2008 Nov;159(5):997-1035. doi: 10.1111/j.1365-2133.2008.08832.x. Epub 2008 Sep 15.
Reference Type
BACKGROUND
Iwase S, Ikeda T, Kitazawa H, Hakusui S, Sugenoya J, Mano T. Altered response in cutaneous sympathetic outflow to mental and thermal stimuli in primary palmoplantar hyperhidrosis. J Auton Nerv Syst. 1997 Jun 6;64(2-3):65-73. doi: 10.1016/s0165-1838(97)00014-3.
Reference Type
BACKGROUND
Bovell DL, Clunes MT, Elder HY, Milsom J, Jenkinson DM. Ultrastructure of the hyperhidrotic eccrine sweat gland. Br J Dermatol. 2001 Aug;145(2):298-301. doi: 10.1046/j.1365-2133.2001.04351.x.
Reference Type
BACKGROUND
Kowalski JW, Eadie N, Dagget S, Lai P-Y. Validity and reliability of the hyperhidrosis disease severity scale (HDSS). J Am Acad Dermatol 2004;50(3):P51.
Reference Type
BACKGROUND
Hoorens I, Ongenae K. Primary focal hyperhidrosis: current treatment options and a step-by-step approach. J Eur Acad Dermatol Venereol. 2012 Jan;26(1):1-8. doi: 10.1111/j.1468-3083.2011.04173.x. Epub 2011 Jul 13.
Reference Type
BACKGROUND
Benson RA, Palin R, Holt PJ, Loftus IM. Diagnosis and management of hyperhidrosis. BMJ. 2013 Nov 25;347:f6800. doi: 10.1136/bmj.f6800. No abstract available.
Reference Type
BACKGROUND
Solish N, Bertucci V, Dansereau A, Hong HC, Lynde C, Lupin M, Smith KC, Storwick G; Canadian Hyperhidrosis Advisory Committee. A comprehensive approach to the recognition, diagnosis, and severity-based treatment of focal hyperhidrosis: recommendations of the Canadian Hyperhidrosis Advisory Committee. Dermatol Surg. 2007 Aug;33(8):908-23. doi: 10.1111/j.1524-4725.2007.33192.x.
Reference Type
BACKGROUND
Wolosker N, Teivelis MP, Krutman M, de Paula RP, de Campos JR, Kauffman P, Puech-Leao P. Long-term results of oxybutynin treatment for palmar hyperhidrosis. Clin Auton Res. 2014 Dec;24(6):297-303. doi: 10.1007/s10286-014-0264-8. Epub 2014 Nov 27.
Reference Type
BACKGROUND
Wolosker N, Krutman M, Teivelis MP, Paula RP, Kauffman P, Campos JR, Puech-Leao P. Analysis of oxybutynin treatment for hyperhidrosis in patients aged over 40 years. Einstein (Sao Paulo). 2014 Jan-Mar;12(1):42-7. doi: 10.1590/s1679-45082014ao2841.
Reference Type
BACKGROUND
Wolosker N, Krutman M, Campdell TP, Kauffman P, Campos JR, Puech-Leao P. Oxybutynin treatment for hyperhidrosis: a comparative analysis between genders. Einstein (Sao Paulo). 2012 Oct-Dec;10(4):405-8. doi: 10.1590/s1679-45082012000400002. English, Portuguese.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
29446
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Evaluation of Phenotypic and Genetic Properties in Male Subjects Affected By Hypohidrotic Ectodermal Dysplasia (ECP-012)
NCT01629927
COMPLETED
Sweat Duct Imaging in Mother/Newborn Dyads
NCT01342133
COMPLETED
Cortisol Activity in Patients With Prader-Willi Syndrome and Healthy Controls
NCT00932932
COMPLETED
Fibrosis and the Fontan
NCT04901975
RECRUITING
PHASE1/PHASE2
The Co-Op @ HeartWorks
NCT06469918
RECRUITING
Short Term Effects and Risks of Physical Exercise in Subjects With Hypohidrotic Ectodermal Dysplasia
NCT01135888
COMPLETED
Children and Adolescents With Marfan Syndrome: 10,000 Healthy Steps and Beyond
NCT03567460
COMPLETED
NA
Adrenocorticotropic Hormone Stimulation in Postural Orthostatic Tachycardia Syndrome (POTS)
NCT01764711
COMPLETED
NA
Study to Evaluate Efficacy of Shunt Operation for Idiopathic Normal Pressure Hydrocephalus
NCT00221091
COMPLETED
PHASE2
Qualitative Sweat Distribution During Tilt Table Procedure
NCT02329548
COMPLETED
NA
Assessment of ShuntCheck Performance Characteristics in Asymptomatic Patients With Normal Pressure Hydrocephalus
NCT04011566
UNKNOWN
The Safety and Efficacy of Adjunct Carvedilol in Children With Moderate Heart Failure
NCT00004854
COMPLETED
PHASE1
Dyskinesia, Heterotaxy and Congenital Heart Disease
NCT00608556
COMPLETED
Clinical Biomarkers in Alpha-mannosidosis
NCT02141503
COMPLETED
Study of Skeletal Disorders
NCT05031507
RECRUITING
Use of Nasal Nitric Oxide Testing in Improving Primary Ciliary Dyskinesia Clinical Care
NCT05287022
RECRUITING
Clinical-Decision Support to Improve Hypertension Care in Primary Care
NCT03404999
COMPLETED
NA
Evaluation of the Safety and Effectiveness of the CereVasc® eShunt® System in Normal Pressure Hydrocephalus
NCT06498960
RECRUITING
NA
Slow Heart Registry of Fetal Immune-mediated High Degree Heart Block
NCT04559425
RECRUITING
Cardiac Function and Morphology Evaluated by Magnetic Resonance Imaging in Growth Hormone Deficiency and Acromegaly
NCT00970463
COMPLETED
Re-Energize Fontan
NCT04195451
RECRUITING
NA
A Prospective Natural History Study of Lymphatic Anomalies
NCT05731141
RECRUITING
Characterization of Sweat Gland Function in Patients With Recessively Inherited Hypohidrotic Ectodermal Dysplasia
NCT01109290
COMPLETED
Measurements of CSF Shunts and Off-Shunt Locations With Wireless Thermal Anisotropy Measurement Devices
NCT06513572
TERMINATED
Medical Record Review of Hypohidrotic Ectodermal Dysplasia Clinical Phenotype
NCT01398397
COMPLETED